TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22578254

Group type: EXPERIMENTAL
Intervention: Psilocybin (215 μg/kg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Ketanserin (50 mg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Psilocybin (215 μg/kg) + Ketanserin (50 mg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 20360777

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 615
Study: 18635480

Group type: EXPERIMENTAL
Intervention: GlideScope videolaryngoscope (GVL)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Direct laryngoscopy (DL)
Number of subjects: 70
Study: 16491671

Group type: EXPERIMENTAL
Intervention: Acetaminophen consumers
Number of subjects: 98

Group type: COMPARATOR
Intervention: Nonconsumers
Number of subjects: 98
Study: 12431855

Group type: EXPERIMENTAL
Intervention: 10 mg d-amphetamine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 20 mg d-amphetamine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 10325291

Group type: EXPERIMENTAL
Intervention: Conservative management
Number of subjects: 108

Group type: COMPARATOR
Intervention: Immediate dilatation and curettage
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Conservative management with detectable pulsatile blood flow
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Conservative management with no detectable flow
Number of subjects: 108
Study: 9191511

Group type: EXPERIMENTAL
Intervention: Once daily beta‐blocker therapy (oral atenolol, 50 to 200 mg)
Number of subjects: 7500

Group type: COMPARATOR
Intervention: Once daily calcium channel blocker therapy (oral diltiazem 120 to 360 mg)
Number of subjects: 7500
Study: 1888800

Group type: EXPERIMENTAL
Intervention: Benzodiazepine therapy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: COMPARATOR
Intervention: Passive viewing task (GAD patients)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Active vigilance task (GAD patients)
Number of subjects: 18
Study: 30262570

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (enoxaparin)
Number of subjects: 949

Group type: EXPERIMENTAL
Intervention: Antithrombin
Number of subjects: 949

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 949
Study: 29710062

Group type: EXPERIMENTAL
Intervention: Home-based resistance exercise program
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study: 27955680

Group type: EXPERIMENTAL
Intervention: Walk This Way (WTW) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 0
Study: 24463121

Group type: EXPERIMENTAL
Intervention: Exercise group (with medications and exercise prescription)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (with medications only)
Number of subjects: 112
Study: 22113064

Group type: EXPERIMENTAL
Intervention: ω‐3 fatty acid‐enriched emulsion (Lipoplus; study group, n = 32)
Number of subjects: 64

Group type: COMPARATOR
Intervention: medium‐chain triacylglycerols/long‐chain triacylglycerols (Lipofundin; control group, n = 32)
Number of subjects: 64
Study: 20844992

Group type: EXPERIMENTAL
Intervention: Non-invasive urodynamic tests
Number of subjects: 41
Study: 17627191

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring system (CGMS)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Standard care supplemented by use of a CGMS
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard care for diabetes
Number of subjects: 20
Study: 15608037

Group type: EXPERIMENTAL
Intervention: GnRH antagonist (0.25 mg of cetrorelix daily starting on day 6 of stimulation)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Long GnRH agonist protocol (600 microg of buserelin acetate daily starting in the mid-luteal phase of the preceding cycle)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Number of subjects: 66

Group type: COMPARATOR
Intervention: Long GnRH agonist protocol
Number of subjects: 66
Study: 12794818

Group type: EXPERIMENTAL
Intervention: leflunomide (100 mg/day for 3 days, then 10 mg/day or 20 mg/day thereafter)
Number of subjects: 214
Study: 10520056

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS)
Number of subjects: 42
Study: 7661113

Group type: EXPERIMENTAL
Intervention: Estimation sample (n = 151)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Validation sample (n = 55)
Number of subjects: 206
Study: 1710395

Group type: EXPERIMENTAL
Intervention: Branched chain‐enriched amino acid mixture (BCAA = 49.4%)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard amino acid infusion (BCAAs = 15.5%)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Leucine intake
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Leucine clearance
Number of subjects: 16
Study: 7425963

Group type: EXPERIMENTAL
Intervention: Twice daily Beclomethasone dipropionate (BDP) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Four times daily Beclomethasone dipropionate (BDP) treatment
Number of subjects: 0
Study: 29401197

Group type: EXPERIMENTAL
Intervention: Experimental Group (EG) performing neuromuscular warm-up exercises (n = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control Group (CG) involved in a standard warm-up (n = 12)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Experimental Group (EG)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 24
Study: 26546010

Group type: EXPERIMENTAL
Intervention: Continuous bed motion
Number of subjects: 68

Group type: COMPARATOR
Intervention: Step-and-shoot
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 68
Study: 23839319

Group type: EXPERIMENTAL
Intervention: 0.05 mcg/kg/min (GROUP A)
Number of subjects: 228

Group type: COMPARATOR
Intervention: 0.1 µg/kg/min (GROUP B)
Number of subjects: 228
Study: 22828481

Group type: EXPERIMENTAL
Intervention: PA-824-moxifloxacin-pyrazinamide (n=13)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Bedaquiline (n=14)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Bedaquiline-pyrazinamide (n=15)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Bedaquiline-PA-824 (n=14)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: PA-824-pyrazinamide (n=14)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard treatment (n=10)
Number of subjects: 66
Study: 19892499

Group type: EXPERIMENTAL
Intervention: Collagen hydrolysates (CH) 10g/day for 24 weeks
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 18306155

Group type: EXPERIMENTAL
Intervention: Infrared device with contact cooling (Titan, Cutera, Brisbane, CA)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Untreated side (control)
Number of subjects: 13
Study: 15830983

Group type: EXPERIMENTAL
Intervention: Disc Coablation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Epidural Injection of Steroids
Number of subjects: 100
Study: 12061355

Group type: EXPERIMENTAL
Intervention: Endurance training regimen (EG1) - 3 sessions per week, 25-35 min per session at intensity >80% of maximal heart rate
Number of subjects: 84

Group type: COMPARATOR
Intervention: Endurance training regimen (EG2) - 2 sessions per week, 15-20 min per session at intensity >80% of maximal heart rate
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group - no training regimen
Number of subjects: 84
Study: 10051289

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg/d)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 7670117

Group type: EXPERIMENTAL
Intervention: Preemptive therapy based on polymerase chain reaction (PCR) technique
Number of subjects: 71

Group type: COMPARATOR
Intervention: Culture assays
Number of subjects: 71
Study: 1688039

Group type: EXPERIMENTAL
Intervention: Xamoterol (200 mg bd orally for 1 month)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 7259982

Group type: EXPERIMENTAL
Intervention: Desoximetasone emollient cream 0.25% applied twice daily
Number of subjects: 22

Group type: COMPARATOR
Intervention: Betamethasone 17-valerate 0.1% cream applied twice daily
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Desoximetasone emollient cream
Number of subjects: 22
Study: 31200708

Group type: EXPERIMENTAL
Intervention: Infiltration resin plus fluoride
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Infiltration resin plus CPP-ACP
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Infiltration resin
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: CPP-ACP plus fluoride
Number of subjects: 120

Group type: COMPARATOR
Intervention: Irradiation control
Number of subjects: 120

Group type: COMPARATOR
Intervention: Blank control
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Irradiation + fluoride
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Irradiation + CPP-ACP
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Irradiation + CPP-ACP + fluoride
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Irradiation + infiltration resin
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Irradiation + infiltration resin + fluoride
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Irradiation + infiltration resin + CPP-ACP
Number of subjects: 120
Study: 29237441

Group type: EXPERIMENTAL
Intervention: Bosentan treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 24
Study: 25660917

Group type: COMPARATOR
Intervention: 1 to 2.4 hours of jogging per week
Number of subjects: 5048

Group type: COMPARATOR
Intervention: Jogging frequency of 2 to 3 times per week
Number of subjects: 5048

Group type: COMPARATOR
Intervention: Jogging frequency of ≤1 time per week
Number of subjects: 5048

Group type: COMPARATOR
Intervention: Slow jogging pace
Number of subjects: 5048

Group type: COMPARATOR
Intervention: Average jogging pace
Number of subjects: 5048

Group type: COMPARATOR
Intervention: Light joggers
Number of subjects: 5048

Group type: COMPARATOR
Intervention: Moderate joggers
Number of subjects: 5048

Group type: COMPARATOR
Intervention: Strenuous joggers
Number of subjects: 5048
Study: 23569140

Group type: EXPERIMENTAL
Intervention: Routine treatment with pelvic floor exercises for 24 weeks
Number of subjects: 47

Group type: COMPARATOR
Intervention: Routine treatment (ultrasonography, short wave diathermy and lumbar strengthening exercises) for 24 weeks
Number of subjects: 47
Study: 21991949

Group type: EXPERIMENTAL
Intervention: AC-T plus trastuzumab
Number of subjects: 3222

Group type: EXPERIMENTAL
Intervention: TCH
Number of subjects: 3222

Group type: COMPARATOR
Intervention: AC-T
Number of subjects: 3222
Study: 19422627

Group type: EXPERIMENTAL
Intervention: Alcohol (0.82 g/kg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 54
Study: 16920764

Group type: EXPERIMENTAL
Intervention: QRS duration >=100 ms
Number of subjects: 562

Group type: EXPERIMENTAL
Intervention: QRS duration >=120 ms
Number of subjects: 562
Study: 15274384

Group type: EXPERIMENTAL
Intervention: Epoetin beta, 30,000 IU per week in three divided doses, with iron supplementation when needed.
Number of subjects: 29
Study: 11762790

Group type: COMPARATOR
Intervention: Sodium bicarbonate (2 weeks)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Potassium citrate (2 weeks)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Potassium citrate and sodium bicarbonate
Number of subjects: 14
Study: 9405902

Group type: EXPERIMENTAL
Intervention: Podiatrist care (education and primary prevention measures)
Number of subjects: 733

Group type: COMPARATOR
Intervention: Control group (written instructions only)
Number of subjects: 733
Study: 8010420

Group type: EXPERIMENTAL
Intervention: Hyperbaric lidocaine 5% solution in a single bolus of 75 mg
Number of subjects: 55

Group type: COMPARATOR
Intervention: Hyperbaric lidocaine 2.5% solution in increments of 25 mg (maximum of three doses)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Titrated doses of 50 mg (n = 15)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Titrated doses of 75 mg (n = 15)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Titrated doses (overall)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: All groups (SD, TD50, TD75)
Number of subjects: 55
Study: 2909593

Group type: EXPERIMENTAL
Intervention: Vitamin/mineral supplement
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49

Group type: COMPARATOR
Intervention: No treatment (adequate diet)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Abnormal menses
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: BMI less than 19.0
Number of subjects: 49
Study: 31296256

Group type: EXPERIMENTAL
Intervention: Higher dose of TGFβ blocking antibody fresolimumab (10 mg/kg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Lower dose of TGFβ blocking antibody fresolimumab (1 mg/kg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with fresolimumab
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: In vitro PD-1 blockade
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Baseline T cell functionality
Number of subjects: 15
Study: 26135067

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 24244395

Group type: EXPERIMENTAL
Intervention: Improved salt-restriction spoon and health education
Number of subjects: 403

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 403
Study: 21146229

Group type: EXPERIMENTAL
Intervention: 0.3 mg quarterly
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: 0.5 mg quarterly
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: 0.3 mg monthly
Number of subjects: 353

Group type: COMPARATOR
Intervention: 0.3 mg quarterly and 0.5 mg quarterly
Number of subjects: 353
Study: 19034249

Group type: COMPARATOR
Intervention: 0.5% plain bupivacaine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine
Number of subjects: 50
Study: 19088594

Group type: EXPERIMENTAL
Intervention: High-fidelity simulation-based training program (ECMO Sim)
Number of subjects: 9
Study: 14622685

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl with local heat applied for 4 hours and again for 1 hour at 24 hours (Session B)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Transdermal fentanyl without local heat (Session A)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl with heat applied for 15 minutes at 12 and 16 hours (Session C)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Transdermal fentanyl without heat (Session A)
Number of subjects: 10
Study: 10890611

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (ventilator therapy without inhaled nitric oxide)
Number of subjects: 32
Study: 9263774

Group type: EXPERIMENTAL
Intervention: AB0 blood group distribution
Number of subjects: 2988

Group type: EXPERIMENTAL
Intervention: Lewis blood group distribution
Number of subjects: 2988

Group type: EXPERIMENTAL
Intervention: Le (a+b‐) donors (non‐secretors)
Number of subjects: 2988

Group type: EXPERIMENTAL
Intervention: Le (a‐b+) frequency
Number of subjects: 2988
Study: 1702235

Group type: EXPERIMENTAL
Intervention: Low dose heparin
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Low dose heparin and graded compression stockings
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Dextran and graded compression stockings
Number of subjects: 245
Study: 6191263

Group type: EXPERIMENTAL
Intervention: Etretinate, CCNU and bleomycin (ECB)
Number of subjects: 46

Group type: COMPARATOR
Intervention: CCNU and bleomycin (CB)
Number of subjects: 46
Study: 30885809

Group type: EXPERIMENTAL
Intervention: Computer-based training program - Massachusetts Eye & Ear ROP Trainer
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard print material on ROP (Control)
Number of subjects: 60
Study: 28287046

Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: No tap (NT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo tap (PT)
Number of subjects: 18
Study: 26325246

Group type: EXPERIMENTAL
Intervention: 400 IU vitamin D3/day
Number of subjects: 55

Group type: COMPARATOR
Intervention: 800 IU vitamin D3/day
Number of subjects: 55

Group type: COMPARATOR
Intervention: 1,200 IU vitamin D3/day
Number of subjects: 55
Study: 24481910

Group type: EXPERIMENTAL
Intervention: ranolazine
Number of subjects: 6543

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6543
Study: 21573819

Group type: EXPERIMENTAL
Intervention: Daily sulphate‐bicarbonate‐calcium mineral water bath
Number of subjects: 60

Group type: COMPARATOR
Intervention: Regular outpatient care routine (Control)
Number of subjects: 60
Study: 19087001

Group type: EXPERIMENTAL
Intervention: Sub-Tenon's anaesthesia
Number of subjects: 50

Group type: COMPARATOR
Intervention: Peribulbar anaesthesia
Number of subjects: 50
Study: 17307426

Group type: EXPERIMENTAL
Intervention: rosiglitazone 4 mg once daily
Number of subjects: 92

Group type: COMPARATOR
Intervention: metformin 850 mg twice daily
Number of subjects: 92
Study: 14985866

Group type: EXPERIMENTAL
Intervention: 99mTc-DTPA excretion method
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional peritoneal equilibrium test
Number of subjects: 20
Study: 11794148

Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5 mg once daily, initiated postoperatively
Number of subjects: 1711

Group type: COMPARATOR
Intervention: Enoxaparin 40 mg once daily, initiated preoperatively
Number of subjects: 1711
Study: 9608824

Group type: EXPERIMENTAL
Intervention: Nasal administration of fenoterol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhalation of beta2-agonists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Frequent administration of small doses of beta2-agonists
Number of subjects: 0
Study: 9356783

Group type: EXPERIMENTAL
Intervention: Calcium antagonists
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitors
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (no drug treatment during washout)
Number of subjects: 96
Study: 2626455

Group type: EXPERIMENTAL
Intervention: d-amphetamine 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: d-amphetamine 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: d-amphetamine 20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11545

Group type: EXPERIMENTAL
Intervention: Corticosteroids and Salazopyrin treatment postoperatively for 33 weeks
Number of subjects: 84

Group type: COMPARATOR
Intervention: No medical treatment postoperatively
Number of subjects: 84
Study: 31762471

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (Normal Saline)
Number of subjects: 120
Study: 30790211

Group type: EXPERIMENTAL
Intervention: Immersive audio-visual respiratory bio-feedback
Number of subjects: 16

Group type: COMPARATOR
Intervention: No pre-sleep arousal manipulation (control)
Number of subjects: 16
Study: 28453348

Group type: EXPERIMENTAL
Intervention: Therapeutic whirlpool
Number of subjects: 60

Group type: COMPARATOR
Intervention: Moist hot pack treatment
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 60
Study: 26255475

Group type: EXPERIMENTAL
Intervention: T‐shaped locking internal fixation
Number of subjects: 100

Group type: COMPARATOR
Intervention: External fixation
Number of subjects: 100
Study: 23064404

Group type: EXPERIMENTAL
Intervention: Vitamin E + placebo
Number of subjects: 35533

Group type: EXPERIMENTAL
Intervention: Selenium + placebo
Number of subjects: 35533

Group type: EXPERIMENTAL
Intervention: Vitamin E + selenium
Number of subjects: 35533

Group type: EXPERIMENTAL
Intervention: Placebo + placebo
Number of subjects: 35533

Group type: EXPERIMENTAL
Intervention: Centralized Follow-Up (CFU) study
Number of subjects: 35533

Group type: EXPERIMENTAL
Intervention: CFU study
Number of subjects: 35533

Group type: EXPERIMENTAL
Intervention: SELECT biorepository
Number of subjects: 35533
Study: 21619383

Group type: EXPERIMENTAL
Intervention: AZD1305 (test dose 250 mg, evening dose 125 mg on day 1, maintenance dose 125 mg twice daily)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: AZD1305 (test dose 500 mg, placebo evening dose, maintenance dose 125 mg twice daily)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo (placebo test and maintenance dose)
Number of subjects: 65
Study: 19345063

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 41
Study: 16720089

Group type: EXPERIMENTAL
Intervention: Guided self-determination group training (GSD-GT) for 16 hours
Number of subjects: 50
Study: 15152127

Group type: EXPERIMENTAL
Intervention: Early sheath removal (group A)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Late sheath removal (group B)
Number of subjects: 267
Study: 11069791

Group type: EXPERIMENTAL
Intervention: Supervised IPT (900 mg twice weekly for 6 months, Regimen A)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Unsupervised IPT (900 mg twice weekly for 6 months, Regimen B)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Unsupervised IPT (300 mg daily for 6 months, Regimen C)
Number of subjects: 208
Study: 9713652

Group type: EXPERIMENTAL
Intervention: Daily rhuIL-2 therapy
Number of subjects: 27

Group type: COMPARATOR
Intervention: Pulse rhuIL-2 therapy
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 27
Study: 8347386

Group type: EXPERIMENTAL
Intervention: Monthly feedback with peer comparison
Number of subjects: 183

Group type: COMPARATOR
Intervention: Feedback (general)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Feedback (intensity correlation)
Number of subjects: 183
Study: 3940334

Group type: EXPERIMENTAL
Intervention: Manual stimulation
Number of subjects: 200

Group type: COMPARATOR
Intervention: Heating pad
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Breast pump
Number of subjects: 200
Study: 30157389

Group type: EXPERIMENTAL
Intervention: Emicizumab 1.5 mg/kg/week (group A)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Emicizumab 3.0 mg/kg every 2 weeks (group B)
Number of subjects: 152

Group type: COMPARATOR
Intervention: No prophylaxis (group C)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Emicizumab prophylaxis vs previous factor VIII prophylaxis (intraindividual comparison)
Number of subjects: 152